Log in

RegulatoryBusiness Standard

USFDA issues 7 observations to NATCO Pharma

Negative-337 sources

GreyOak summary

NATCO Pharma Limited received seven observations from the USFDA following an inspection of its Hyderabad manufacturing facility conducted between November 12 and 20. The regulator cited conditions that may constitute violations of laws in Form 483. The company stated these observations are procedural and expressed confidence in addressing them within the stipulated timelines.

What it affects

Source

Reported by Business Standard

  • Business Today
  • BusinessLine
  • Economic Times
  • Economic Times
  • Economic Times
  • CNBC-TV18
  • Business Standard

More Natco Pharma news

All Natco Pharma news →

The company today

Price, day change, sector and market cap of the companies this story names
CompanyPriceDay changeSectorMarket cap
Natco PharmaNATCOPHARM · NSE₹814.30−0.93%Healthcare₹15,974 crore

Prices as of ; the last session's close when the market is shut. Research, not investment advice.

Latest market news

News Intelligence →

We use cookies

Essential cookies keep GreyOak secure and functional. Optional cookies help improve your experience and platform performance. You can update your preferences anytime.

Cookie Policy